More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance therapy, researchers from the Abramson Cancer Center (ACC)…
Read More
Researchers discover new inhibitor drug combination for rare form of cancer
Waldenström macroglobulinemia (WM), a rare form of lymphoma, does not have any known cure and only one FDA-approved treatment making it challenging to treat patients. Researchers at the University of New Hampshire took the novel approach of targeting specific cell…
Read More
Immune checkpoint inhibitor therapy tied to cardiac event risk
(HealthDay)—Immune checkpoint inhibitor (ICI) treatment is associated with increased cardiac events among patients with lung cancer and malignant melanoma, according to a study published online Dec. 9 in the European Heart Journal. Maria D’Souza, M.D., from the Copenhagen University Hospital…
Read More